Colossal
Build radical new software tools and technologies to advance the science of genomics overall.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
* | N/A | Corporate spinout | |
$15.0m | Seed | ||
* | $15.0m | Seed | |
* | $60.0m | Series A | |
* | N/A | Early VC | |
* | $150m Valuation: $1.0b | Series B | |
| N/A | N/A | Series B | |
* | N/A | $50.0m Valuation: $1.0b | Late VC |
* | $200m Valuation: $10.2b | Series C | |
| Total Funding | $490m | ||
| USD | 2022 | 2023 |
|---|---|---|
| Revenues | 0000 | 0000 |
| % growth | - | 157 % |
| EBITDA | 0000 | 0000 |
| Profit | 0000 | 0000 |
| EV | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 |
Source: Dealroom estimates
Related Content
Colossal is a cutting-edge genetics and biosciences company that is working to save our planet and the species that inhabit it. The company is focused on developing a functional application of advanced gene editing technology to rebuild the DNA of lost megafauna and other creatures that had a positive impact on our fragile ecosystems. They are currently in the process of the de-extinction of the Woolly Mammoth, having collected viable DNA samples and editing the genes that will allow it to once again thunder through the Arctic.
Colossal is led by Ben Lamm and world-renowned geneticist and serial biotech founder George Church, Ph.D. The company is different from other businesses in the same industry in that it is focused on utilizing the science of genetics to jumpstart nature’s ancestral heartbeat and advance the economies of biology and healing through genetics.
Colossal is making a profit by leveraging the world’s leading scientists to develop advanced gene editing technology that can be applied to species that are being driven to extinction. The company is also working to make humanity more human by reawakening the lost wilds of Earth, so that we and our planet can breathe easier.
